1051971-74-4

Usage

Uses

Given the provided materials, the specific uses of Dibromo zinc bis[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]porphyrin-ethinyl dimer are not explicitly detailed. However, based on its potential applications in fields such as organic chemistry, materials science, and medicine, we can infer the following uses:
Used in Organic Chemistry:
Dibromo zinc bis[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]porphyrin-ethinyl dimer is used as a complex organic molecule for [application reason, e.g., its unique structure may be utilized in the synthesis of new organic compounds or as a precursor in organic reactions].
Used in Materials Science:
In materials science, Dibromo zinc bis[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]porphyrin-ethinyl dimer is used as a component in the development of advanced materials for [application reason, e.g., its specific properties might contribute to the creation of new materials with unique electronic, optical, or mechanical characteristics].
Used in Medicine:
Dibromo zinc bis[3-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]phenyl]porphyrin-ethinyl dimer is used as a potential pharmaceutical agent for [application reason, e.g., its structure may have implications for drug design or as a component in medical imaging or therapeutics].

Upstream product

• 1062503-88-1 Zn((MeO(CH₂CH₂O)3C₆H₄)2(HCC)(Br)C₂₀H₈N₂) 
• 1062503-88-1 C₄₈H₄₇BrN₄O₈Zn 

Downstream Products

• 1062503-93-8 C₁₀₆H₁₀₀N₁₀O₁₆Zn₂ 
• 1051971-75-5 C₁₁₀H₁₀₀N₁₀O₁₆Zn₂ 
• 1051971-75-5 Zn₂((MeO(CH₂CH₂O)3C₆H₄)2(NC₅H₄CC)C₂₀H₈N₄C₄C₂₀H₈N₄(C₆H₄(OCH₂CH₂)3OMe)2(CCC₅H₄N)) 
• 1062503-93-8 Zn₂((MeO(CH₂CH₂O)3C₆H₄)2(NC₅H₄)C₂₀H₈N₂C₄C₂₀H₈N₄(C₅H₄N)(C₆H₄(OCH₂CH₂)3OMe)2) 

Relevant academic research and scientific papers

Synthesis of hydrophilic conjugated porphyrin dimers for one-photon and two-photon photodynamic therapy at NIR wavelengths

We report the synthesis of a series of hydrophilic butadiyne-linked conjugated zinc porphyrin dimers (1-7), designed as photodynamic therapy (PDT) agents. These porphyrin dimers exhibit exceptionally high two-photon absorption cross sections (δmax≈ 8,000-17,000 GM) and red-shifted linear absorption spectra (λmax≈ 700-800 nm) making them ideal candidates for one-photon and two-photon excited photodynamic therapy. Four polar triethyleneglycol substituents are positioned along the sides of each dimer, but, on their own, these TEG chains do not confer sufficient solubility in aqueous physiological media for reproducible delivery into live cells. Charged cationic (methylpyridinium and trimethylammonium) and anionic (sulfonate and carboxylate) substituents have been appended to the meso-positions of porphyrin dimers using three synthetic strategies: 1) Suzuki coupling, 2) Sonogashira coupling, and 3) nucleophilic Senge arylation. Approaches 1 and 3 both allow attachment of aromatic substituents directly to the meso-positions of porphyrins. Approach 2 provides a route to hydrophilic porphyrin dimers with an ethyne link between the porphyrin and the polar aromatic substituent. The palladium-catalysed approaches 1 and 2 allow the synthesis of a broader range of meso-capped porphyrins, as many aryl halides are available. However the synthesis of the intermediate required for these routes necessitates a statistical reaction step, which decreases the overall yield. On the other hand, Senge-arylation provides highly regioselective nucleophilic aromatic substitution, and offers higher overall yield than the other routes. All these charged dimers exhibit good solubility in polar solvents (e.g. methanol) and aqueous solvent mixtures (aqueous DMSO or DMF).

PORPHYRIN COMPOUNDS

The present invention relates to porphyrin compounds of formula (I), to processes for preparing said compounds, to pharmaceutical compositions comprising said compounds and their use in photodynamic therapy. The porphyrin compounds exhibit high two photon absorption cross section values, are soluble and are readily absorbed by cells making them suitable for use in two photon photodynamic therapy.